HeartiCellgram-AMI(HeartiCellgram-AMI) - 在研适应症：急性心肌梗塞_专利_临床

概要

基本信息

药物类型

间充质干细胞疗法

别名

Autologous bone marrow derived mesenchymal stem cells

靶点-

作用机制

干细胞替代物

治疗领域

心血管疾病

在研适应症

急性心肌梗塞

非在研适应症-

原研机构

Pharmicell Co., Ltd.

在研机构

Pharmicell Co., Ltd.

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

5

项与 HeartiCellgram-AMI 相关的临床试验

EUCTR2018-004067-31-CZ / Not yet recruiting临床1/2期IIT

Autologous bone marrow-derived mesenchymal stem cells seeded on a 3D scaffold in treatment of knee cartilage defects. Prospective open-label study to assess safety and feasibility.

开始日期2018-12-21

申办/合作机构

Bioinova, s.r.o.

CTRI/2015/04/005716 / Recruiting临床1/2期IIT

A Pilot Study on the Efficacy of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Systemic Lupus Erythematosus

开始日期2015-03-02

申办/合作机构-

NCT01652209 / Active, not recruiting临床3期

A Randomized,Open labEled, muLticenter Trial for Safety and Efficacy of Intracoronary Adult Human Mesenchymal stEm Cells Acute Myocardial inFarction

Through the injection of Hearticellgram-AMI into acute myocardial infarction patients who are the primary targets of the drug, long term efficacy in the improvement of the left ventricle ejection fraction upon the first cell treatment is to be evaluated and compared with the current existing treatments (contemporary drug treatment).
This study will also compare the efficacy and safety of single dose of hearticellgram-AMI.

开始日期2013-09-01

申办/合作机构

Pharmicell Co., Ltd.

100 项与 HeartiCellgram-AMI 相关的临床结果

登录后查看更多信息

100 项与 HeartiCellgram-AMI 相关的转化医学

登录后查看更多信息

100 项与 HeartiCellgram-AMI 相关的专利（医药）

登录后查看更多信息

100 项与 HeartiCellgram-AMI 相关的药物交易

登录后查看更多信息